Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes - a randomized, single-blinded, cross-over pilot study.

Faber R, Zander M, Pena A, Michelsen MM, Mygind ND, Prescott E

Cardiovascular diabetology22 Apr 2015Cited by 45 (Europe PMC)

PMID25896352PMCIDPMC4407869DOI10.1186/s12933-015-0206-3PepBankPUB-25896352

Summary

BackgroundImpaired coronary microcirculation is associated with a poor prognosis in patients with type 2 diabetes. In the absence of stenosis of major coronary arteries, coronary flow reserve (CFR) reflects coronary microcirculation. Studies have shown beneficial effects of glucagon-like peptide-1 (GLP-1) on the cardiovascular system. The aim of the study was to explore the short-term effect of GLP-1 treatment on coronary microcirculation estimated by CFR in patients with type 2 diabetes.MethodsPatients with type 2 diabetes and no history of coronary artery disease were treated with either the GLP-1 analogue liraglutide or received no treatment for 10 weeks, in a randomized, single-blinded, cross-over setup with a 2 weeks wash-out period. The effect of liraglutide on coronary microcirculation was evaluated using non-invasive trans-thoracic Doppler-flow echocardiography during dipyridamole induced stress. Peripheral microvascular endothelial function was assessed by Endo-PAT2000®. Interventions were compared by two-sample t-test after ensuring no carry over effect.ResultsA total of 24 patients were included. Twenty patients completed the study (15 male; mean age 57 ± 9; mean BMI 33.1 ± 4.4, mean baseline CFR 2.35 ± 0.45). There was a small increase in CFR following liraglutide treatment (change 0.18, CI95% [-0.01; 0.36], p = 0.06) but no difference in effect in comparison with no treatment (difference between treatment allocation 0.16, CI95% [-0.08; 0.40], p = 0.18). Liraglutide significantly reduced glycated haemoglobin (HbA1c) (-10.1 mmol/mol CI95% [-13.9; -6.4], p = 0.01), systolic blood pressure (-10 mmHg CI95% [-17; -3], p = 0.01) and weight (-1.9 kg CI95% [-3.6; -0.2], p = 0.03) compared to no treatment. There was no effect on peripheral microvascular endothelial function after either intervention.ConclusionsIn this short-term treatment study, 10 weeks of liraglutide treatment had no significant effect on neither coronary nor peripheral microvascular function in patients with type 2 diabetes. Further long-term studies, preferably in patients with more impaired microvascular function and using a higher dosage of GLP-1 analogues, are needed to confirm these findings.Trial registrationClinicalTrials.gov: NCT01931982 .

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, coronary flow reserve showed a small, non-significant increase after 10 weeks of liraglutide.
In plain wordsIn adults with type 2 diabetes, 10 weeks of liraglutide gave only a small, non-significant rise in coronary blood flow reserve.
Peptide
Liraglutide
Outcome
No significant changeCoronary flow reserve change on liraglutide
Study
n = 20
Comparator
No treatment
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 10 weeksAs given in this study (human).
Measurements
CFR change
0.18 NA
liraglutide
Source sentences
Summary
There was a small increase in CFR following liraglutide treatment (change 0.18, CI95% [-0.01; 0.36], p = 0.06)
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of liraglutide on coronary microcirculation was evaluated using non-invasive trans-thoracic Doppler-flow echocardiography during dipyridamole induced stress.
Summary · context
Patients with type 2 diabetes and no history of coronary artery disease were treated with either the GLP-1 analogue liraglutide or received no treatment for 10 weeks, in a randomized, single-blinded, cross-over setup with a 2 weeks wash-out period.
Show in the study text Report a problemFND-2589635201
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, coronary flow reserve did not differ between liraglutide and no treatment.
In plain wordsIn adults with type 2 diabetes, coronary blood flow reserve was not different with liraglutide than with no treatment.
Peptide
Liraglutide
Outcome
No significant changeCoronary flow reserve, liraglutide vs no treatment
Study
n = 20
Comparator
No treatment
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 10 weeksAs given in this study (human).
Measurements
CFR difference between treatment allocations
0.16 NA
liraglutide vs no treatment
Source sentences
Summary
but no difference in effect in comparison with no treatment (difference between treatment allocation 0.16, CI95% [-0.08; 0.40], p = 0.18).
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of liraglutide on coronary microcirculation was evaluated using non-invasive trans-thoracic Doppler-flow echocardiography during dipyridamole induced stress.
Summary · context
Patients with type 2 diabetes and no history of coronary artery disease were treated with either the GLP-1 analogue liraglutide or received no treatment for 10 weeks, in a randomized, single-blinded, cross-over setup with a 2 weeks wash-out period.
Show in the study text Report a problemFND-2589635202
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide significantly reduced HbA1c compared with no treatment.
In plain wordsIn adults with type 2 diabetes, liraglutide lowered HbA1c more than no treatment.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change
Study
n = 20
Comparator
No treatment
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 10 weeksAs given in this study (human).
Measurements
HbA1c change
−10.1 mmol/mol
liraglutide vs no treatment
Source sentences
Summary
Liraglutide significantly reduced glycated haemoglobin (HbA1c) (-10.1 mmol/mol CI95% [-13.9; -6.4], p = 0.01)
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of liraglutide on coronary microcirculation was evaluated using non-invasive trans-thoracic Doppler-flow echocardiography during dipyridamole induced stress.
Summary · context
Patients with type 2 diabetes and no history of coronary artery disease were treated with either the GLP-1 analogue liraglutide or received no treatment for 10 weeks, in a randomized, single-blinded, cross-over setup with a 2 weeks wash-out period.
Show in the study text Report a problemFND-2589635203
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide significantly reduced systolic blood pressure compared with no treatment.
In plain wordsIn adults with type 2 diabetes, liraglutide lowered systolic blood pressure more than no treatment.
Peptide
Liraglutide
Outcome
DecreaseSystolic blood pressure change
Study
n = 20
Comparator
No treatment
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 10 weeksAs given in this study (human).
Measurements
Systolic blood pressure change
−10 mmHg
liraglutide vs no treatment
Source sentences
Summary
systolic blood pressure (-10 mmHg CI95% [-17; -3], p = 0.01)
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of liraglutide on coronary microcirculation was evaluated using non-invasive trans-thoracic Doppler-flow echocardiography during dipyridamole induced stress.
Summary · context
Patients with type 2 diabetes and no history of coronary artery disease were treated with either the GLP-1 analogue liraglutide or received no treatment for 10 weeks, in a randomized, single-blinded, cross-over setup with a 2 weeks wash-out period.
Show in the study text Report a problemFND-2589635204
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide significantly reduced weight compared with no treatment.
In plain wordsIn adults with type 2 diabetes, liraglutide lowered body weight more than no treatment.
Peptide
Liraglutide
Outcome
DecreaseWeight change
Study
n = 20
Comparator
No treatment
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 10 weeksAs given in this study (human).
Measurements
Weight change
−1.9 kg
liraglutide vs no treatment
Source sentences
Summary
and weight (-1.9 kg CI95% [-3.6; -0.2], p = 0.03) compared to no treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of liraglutide on coronary microcirculation was evaluated using non-invasive trans-thoracic Doppler-flow echocardiography during dipyridamole induced stress.
Summary · context
Patients with type 2 diabetes and no history of coronary artery disease were treated with either the GLP-1 analogue liraglutide or received no treatment for 10 weeks, in a randomized, single-blinded, cross-over setup with a 2 weeks wash-out period.
Show in the study text Report a problemFND-2589635205
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, 10 weeks of liraglutide had no effect on peripheral microvascular endothelial function.
In plain wordsIn adults with type 2 diabetes, 10 weeks of liraglutide did not change the function of small blood vessels in the periphery.
Peptide
Liraglutide
Outcome
No significant changePeripheral microvascular endothelial function
Study
n = 20
Comparator
No treatment
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 10 weeksAs given in this study (human).
Source sentences
Summary
There was no effect on peripheral microvascular endothelial function after either intervention.
2 context sentences(design, population, supporting numbers)
Summary · context
Peripheral microvascular endothelial function was assessed by Endo-PAT2000®.
Summary · context
Patients with type 2 diabetes and no history of coronary artery disease were treated with either the GLP-1 analogue liraglutide or received no treatment for 10 weeks, in a randomized, single-blinded, cross-over setup with a 2 weeks wash-out period.
Show in the study text Report a problemFND-2589635206

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT02602600

Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary Stenosis

Eva Prescottn = 3319 Nov 2015 to 18 Apr 2017

Microvascular Angina

Trial page ClinicalTrials.govUpdated 11 Jul 2018

CompletedPhase 4NCT01931982

Effect of Glucagon-like Peptide 1 (GLP-1) on Microvascular Myocardial Function in Patients With Type 2 Diabetes.

Bispebjerg Hospitaln = 20May 2013 to Apr 2014

Type 2 Diabetes · Microvascular Dysfunction

Trial page ClinicalTrials.govUpdated 25 Jun 2014

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.